Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Molycorp: Morgan Brothers' Reverse Convertible Notes (C)
Esty, Benjamin C.; Mayfield, E. ScottCaso HBS-215002-EFinanzasIn August 2011, Morgan Brothers Bank was issuing a $2.5 million reverse convertible note with payoffs linked to the price of Molycorp's common stock. These financially engineered securities were just one of many kinds of structured notes available in the retail market. Investors must decide whether the notes were fairly priced and whether they offered a favorable risk-return trade-off.Desde 5,74 €
-
E-Commerce Analytics for CPG Firms(C): Free Delivery Terms
Israeli, Ayelet; Lisitsyn, Fedor TedCaso HBS-521080-EMarketingThe E-Commerce Analytics group at the traditional CPG firm was in charge of compiling various online sales reports, as well as making data-driven recommendations for sales and marketing tactics. In a series of exercises, students address different data chDesde 5,74 €
-
Graphic Packaging: Project Cowboy (A, B, C, & D), Teaching Note
Esty, Benjamin C.; Mayfield, E. ScottNota del Instructor HBS-223087-EFinanzasTeaching note to cases 223009, 223066, 223068, and 223086.Desde 0,00 €
-
Gillette Company (A), (B), (C), (D), and (E), Teaching Note
Kanter, Rosabeth Moss; Bird, MatthewNota del Instructor HBS-312114-ELiderazgo y Dirección de personasTeaching Note for 303032, 303033, 303034, 303035, 309033.Desde 0,00 €
-
PG&E and the First Climate Change Bankruptcy
Gilson, Stuart C.; Abbott, Sarah L.Caso HBS-221057-EFinanzasIn early 2020, the California-based utility PG&E filed a second amended plan of reorganization. PG&E had filed for Chapter 11 bankruptcy in the face of more than $30 billion of legal claims brought against it for its alleged role in causing California wildfires. The plan had the support of key creditors and shareholders and a court-appointed committee representing the wildfire victims. However, it faced strong opposition from California's governo...Desde 8,20 €
-
Global Knowledge Management at Danone (C)
Edmondson, Amy C.; Dittrich, Ruth; Beyersdorfer, DanielaCaso HBS-611080-EServicios y operacionesThe (C) case provides an update on the B-case decision and describes the introduction of Dan 2.0, an internal social virtual network for the purpose of knowledge sharing in a company that was only used to face-to-face networking.Desde 5,74 €
-
e-Consulting (Spanish version)
Nanda, Ashish; DeLong, Thomas J.; Landry, Scot; Agan, Thomas E.Caso HBS-804S07Servicios y operacionesProporciona una visión general de la historia y el desarrollo de la industria del e-consulta, así como las cuestiones que se le plantean.Desde 8,20 €
-
Mistry Architects (C)
Edmondson, Amy C.; Eccles, Robert G.; Sinha, MonaCaso HBS-609086-EThis case is a follow-up of "Mistry Architects: Innovating for Sustainability" (A) (Case 609-044) and (B) (Case 609-086). In Case (A) Sharukh and Renu Mistry founded and run an architectural firm dedicated to being both client-oriented and environmentally responsible. The case uses a difficult design decision in a tsunami rehabilitation project to illustrate the challenges faced by professional services firms, and the role of innovation in meetin...Desde 5,74 €
-
Arck Systems (A), (B), (C), (D), (E) and (F), Teaching Note
Larkin, Ian I.Nota del Instructor HBS-911074-ELiderazgo y Dirección de personasTeaching Note for 911056, 911057, 911058, 911059, 911060 and 911073.Desde 0,00 €
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Caso HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Desde 8,20 €